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highly effective and safe primary treatment modality. Initial thrombosis rates exceeded
90% and no serious complications were observed in this series despite a high rate of
concomitant antiplatelet and antithrombotic therapy.
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Background: The preclose technique with the 6 F Proglide for complete percutaneous
endovascular aortic repair have not been sufficiently evaluated. We investigated the
efficacy and safety of the preclose technique in a sufficient and large cases.
Methods: The medical records of 367 patients with 599 preclose techniques for various
aortic repairs were reviewed. Procedural success was defined as hemostasis achieved by
the preclose technique, without the need for surgical or endovascular procedures. Access
related major adverse event (ARMAE)s were considered as those event, such as infection,
bleeding, new onset ischemia of the lower leg, hematoma, pseudoaneurysm, arteriovenous
fistula, embolization, laceration, femoral artery thrombosis, nerve injury, or death by
access site injury.
Results: Procedural success was achieved in 359 of 367 patients (97.8%) and 591 of 599
left or right femoral sites (98.7%). All cases of procedural failure were treated by
immediate surgical repair of femoral arteries. The preclose technique was more successful
in the smaller sheath. ARMAEs developed in 25 of 367 patients (6.8%) and 26 of 599
sites (4.3%). Access site hematoma was the most frequent adverse events (16 of 367
patients (4.4%) and 17 of 599 sites (2.8%)), followed by puncture site pseudoaneurysm (7
of 367 patients (1.9%) and 7 of 599 sites (1.2%)). Bleeding after arterial closure occurred
in 6 of 367 patients (1.6%) and 6 of 599 sites (1.0%). In 2 of 367 patients (0.5%), there
was an infection at the puncture site. There were two cases of distal embolization, one case
of acute femoral thrombosis, and one case of a vascular laceration at the puncture site.
There were no access site related nerve injury, arteriovenous fistula or death complicated
by access site.
Conclusions: The preclose technique can be used to achieve hemostasis for stent graft
procedure successfully, with a high rate of procedural success and an acceptable rate of
adverse event, the most common being puncture site hematoma formation.
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Background: Transradial approach (TRA) in percutaneous coronary intervention (PCI)
has increased over the past few years. Its use has been shown to decrease mortality
compared with the transfemoral approach (TFA) in patients with acute coronary
syndrome (ACS). Comparative studies have systematically excluded patients with
cardiogenic shock (CS).
Methods: We carried out a prospective, observational registry study of consecutive
patients undergoing emergent revascularization between February 2007 and January
2012. An analysis of the clinical evolution of patients with CS during hospitalization was
performed according to the approach used in the PCI.
Results: Of 1,400 emergency procedures, 122 had CS, 80 underwent PCI by TRA
(65.6%) and 42 by TFA (34.3%). The main reason for choosing TFA was the absence of
radial pulse (54.9%). Mortality (64.3% vs. 32.5%, p0.001), serious access site
complications (11.9% vs. 2.5%, p0.03) and MACE (combination of death, infarction,
stroke, serious bleeding, and postanoxemic encephalopathy) (73.8% vs. 43.8%, p0.001)
were greater in TFA patients. In the multivariate analysis, TRA was a predictor of
mortality (OR 0.39[0.15-0.97]); other predictive factors were age75 (3.47[1.35-8.92]),
previous treatment with diuretics (3.67[1.21-11.12]) and the success of the procedure
(0.08[0.02-0.24]).
Conclusions: In centers with experience, TRA approach for PCI is possible and safe in
patients with CS in up to two thirds of the patients. The main cause that prevented the use
of TRA was the absence of radial pulse. In the multivariate analysis, TRA was associated
with a lower risk of mortality.
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Background: Ballooon aortic valvulplasty can be useful for palliation of symptoms in
pts not eligible for surgical or transcatheter aortic vaalve replacement, or a a bridge to
AVR. Occassionally transfemoral access is impossible or challenging, due to vascular
disease or morbid obesity. We present our experience with trasnradial access for balloon
aortic valvulplasty in pts not candidates for transfemoral approach.
Methods: 5 pts presented with critical aortic stenosis without femoral access. Transradial
access was successfully obtained in all pts. In 1 pt a vascular loop prompted a change from
the right to the left radial approach - the others were done via right radial access. Internal
jugular venous access was used for PA catheter and pacing. After crossing the aortic valve
using 6Fr amplatz 1 catheter with straight wire, and changing out for a dual lumen pigtail.
Over an exchange length wire, the 6 Fr sheath was excheanged for an 8 Fr, and a 22 mm
Tyshack balloon was advanced across the aortic valve and dilated during rapid pacing.
Due to inadequate hemodynamics, in 1 case the 8 Fr sheath was exchanged for a 9 Fr, and
a 25 mm Tyshack balloon used.
Results: In 4 of 5 pts aortic valvuloplasty was attempted and successfully performed. In
1 pt with morbid orbesity vigourous diuresis was instead successful in treating his CHF
and one year later he underwent successful surgical AVR. 1 of the pts with successful
balloon valvuplasty had occlusive lower extremity arterial disease and need for warfarin
for a mechanical mitral valve, the others had morbid obesity (mean weight 168 kg). All
pts had hemodynamic improvement, mean AV gradient decreased from 47 to 36 (23%),
and AVA increased from 0.85 to 1.1 (29% increase). The pt with 9 Fr sheath had small
amount of tissue removed with removal of the 9 Fr sheath, but no clinical complications
in any pt.
Conclusions: Radial artery access is a feasible option for the performance of balloon
aortic valvuloplasty in patients with poor femoral artery access.
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Background: Vascular Hemostasis Devices (VHD) are regulated by FDA as high-risk
Class III medical devices requiring Pre-Market Approval (PMA). First approved in 1995,
these devices have evolved and been broadly adopted for hemostasis use, with current use
estimates up to 50% of all coronary procedures. FDA databases were searched to provide
a regulatory summary and device profile overview.
Methods: The PMA, Adverse Event, Recall, Registration and Inspection databases were
searched using the device product code and years 2007 through 2011. Statistical testing
used t-test and X2, as appropriate for proportions or means, with significance level of 0.05.
Results: The FDA registration and listing database identified 8 different manufacturers
and 11 different devices. FDA approval of the 11 devices occurred from 1995 through
2011. 10 of the 11 listed devices are made in the US by US manufacturers. Two
manufacturers represented 95% of the VHDs reported in adverse events. The number of
annual adverse events reports increased 300% from 1,402 in 2007 to 4,243 in 2011, with
a five year total of 14,120 reports received. Geographically, 72% of the adverse events
occurred in the US and 27% in 53 other countries. Females were disproportionately
represented (p 0.001, 44% vs. 34% expected). Patient age ranged from 4 to 98 years,
with women found to be older than men (65.8 vs. 64.7, p0.01). A total of 164 reports
for death as the patient outcome were received. For women, deaths were present in 3.38%
of the reports compared to 1.28% for men (p0.001, odds ratio 2.7 [CI 1.908, 3.802]).
During the timeframe there was one US recall for a compromised sterility issue and one
foreign recall for increased failure rates. US Manufacturer and contractor inspections
included four cases of FDA citations requiring actions.
Conclusions: Reasons women experience higher risks are not known but appear to
persist despite product experience and design changes. More research on gender
differences and device design is recommended. Increased overall numbers of VHD
adverse event reports to FDA likely parallels temporal increases in use. Limitations relate
to missing data for patient age and gender, and known underreporting of adverse events.
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Background: The Sheathless Guiding Catheter (SGC) (Sheathless Eaucath, Asahi Intecc
Co, Japan) has Hydrophilic coatings that enhances catheter tractability through tortuous
vessels and allow dealing with radial spasm and performing Percutaneous Coronary
Intervention (PCI) by radial approach in complex cases. We reported our experience in 91
patients (pts) with complex transradial approach in whom SGC was used to avoid femoral
cross over to complete the procedure.
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